ALDEI Deinove S.A.

New industrial-scale production of Phyt-N-Resist® to supply the market

New industrial-scale production of Phyt-N-Resist® to supply the market

 

New industrial-scale production of Phyt-N-Resist®

to supply the market

  • DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future customers.
  • Several projects for the development of cosmetic products containing the first DEINOVE’s active made of Phytoene are underway.

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics and nutrition, announces the production of a new industrial batch of Phyt-N-Resist®, its first proprietary cosmetic active ingredient, to meet the needs of its distributors and future customers.

Phyt-N-Resist® is a colorless carotenoid with clinically proven antioxidant and regenerative properties. This first 100% pure Phytoene is an anti-aging active ingredient whose mechanism of action reveals a prime target for cell regeneration: laminin, a protein that links the different types of collagen and contributes to the adhesion of the epidermis to the dermis.

DEINOVE has developed an exclusive process for the bioproduction and extraction of Phytoene. 100% naturally-sourced and vegan, produced exclusively in France, it is derived from fermentation of plant sugars by the extremophile microorganism Deinococcus geothermalis. Phyt-N-Resist® has been sampled by nearly a hundred cosmetic brands and incorporated into various skincare formulations, demonstrating its potential in several strategic markets. The partners for distribution of this active ingredient are Solvay in the Americas and Asia, and Univar in EMEA.

"Phyt-N-Resist® has been tested in different formulations and several tangible projects for the development of cosmetic products containing this active ingredient have been identified. Our distributors work closely with these brands located in different geographical areas. This new industrial batch is essential to address market needs and supply future customers" says Coralie MARTIN, Marketing Manager at DEINOVE.



ABOUT PHYTOENE

A breakthrough in naturally-sourced active ingredients: DEINOVE bioproduced the 1st pure Phytoene.

Both skin cells and plants rely on a common substance to protect themselves from oxidative stress: Phytoene, the original precursor of all carotenoids. However, unlike plants, skin cannot synthesize it. Phytoene counts among these essential molecules that need to be brought through food or external supplementation, either oral or topical.

So far there was no way to extract pure Phytoene. None of the available production processes from plants allows the production of pure Phytoene. They provide only a random mixture of carotenoids, at low concentration, and with varying degrees of stability and colors.

Tapping into the extraordinary resources of biomimetism, harnessing the potential of Deinococcus geothermalis, a UV-resistant extremophile bacterium, DEINOVE has for the first time ever achieved the bioproduction of pure Phytoene.

Extended anti-aging properties

Carotenoids are known for their antioxidant properties. Phytoene has been successfully tested for its ability to reduce the amount of lipoperoxidation products, appearing after cells exposure to UV radiations. Indeed, phytoene accumulates in cellular membranes to prevent cellular degradation. By protecting membranes lipids from free radicals, Phytoene reduces the harmful effects of oxidation and, ultimately, skin aging.

DEINOVE went even further while putting in place a systematic screening of its active ingredients across several dimensions. This comprehensive, innovative approach has highlighted a previously untapped feature under the carotenoid family: cell renewal stimulation. Wounded skin is able to regenerate under the action of phytoene.

These properties were subsequently confirmed by a conclusive clinical study, demonstrating its beneficial effect on skin firmness, elasticity and radiance. Above all, Phytoene has a significant antiwrinkle action.

This makes Phytoene a thorough anti-aging active ingredient for the beauty industry.

ABOUT DEINOVE

DEINOVE is a French biotechnology company, a leader in disruptive innovation, which aims to help meet the challenges of antibiotic resistance and the transition to a sustainable production model for the cosmetics and nutrition industries.

DEINOVE has developed a unique and comprehensive expertise in the field of rare bacteria that it can decipher, culture, and optimize to disclose unsuspected possibilities and induce them to produce biobased molecules with activities of interest on an industrial scale. To do so, DEINOVE has been building and documenting since its creation an unparalleled biodiversity bank that it exploits thanks to a unique technological platform in Europe.

DEINOVE is organized around two areas of expertise:

  • ANTIBIOTICS, New-generation anti-infective agents: A first antibiotic candidate is now in Phase II. The Company is also pursuing the systematic exploration of biodiversity to supply its portfolio with new leads, drawing notably on partnerships with bioMérieux and Naicons (AGIR program supported by Bpifrance).
  • BIOACTIVES, Active ingredients of natural origin with cosmetics as the first market and potential in nutrition and health: DEINOVE is already marketing a first innovative asset, a second in partnership with Greentech and plans to launch new assets in 2020. Several other cosmetic actives are in development, including Oléos (Hallstar Group) and Dow. It also runs a program in animal nutrition with Groupe Avril.

Within the Euromedecine science park located in Montpellier, DEINOVE employs 60 employees, mainly researchers, engineers, and technicians, and has filed more than 350 patent applications internationally. The Company has been listed on EURONEXT GROWTH® since April 2010.

CONTACTS

Investors

Coralie Martin

Communication, Marketing and Investor Relations

Ph.: +33 (0)4 48 19 01 60



Media

ALIZE RP

Caroline Carmagnol

Ph.: +33 (0)6 64 18 99 59



 

Attachment

EN
22/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Deinove S.A.

 PRESS RELEASE

Conversion of the receivership proceedings into judicial liquidation p...

Conversion of the receivership proceedings into judicial liquidation proceedings CONVERSION OF THE RECEIVERSHIP PROCEEDINGS INTO JUDICIAL LIQUIDATION PROCEEDINGS DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that on January 23, 2023, the Montpellier Commercial Court rendered a judgment converting the receivership proceedings, initiated on November 7, 2022, into a judicial liquidation proceedings (“procédure de liquidation jud...

 PRESS RELEASE

Conversion de la procédure de redressement judiciaire en liquidation j...

Conversion de la procédure de redressement judiciaire en liquidation judiciaire CONVERSION DE LA PROCEDURE DE REDRESSEMENT JUDICIAIRE EN LIQUIDATION JUDICIAIRE DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que le Tribunal de Commerce de Montpellier a rendu le 23 janvier 2023 un jugement actant la conversion de la procédure de redressement judiciaire, initiée le 7 novembre 2022, en liquidation jud...

 PRESS RELEASE

DEINOVE - Update on the receivership proceedings

DEINOVE - Update on the receivership proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court met on January 13, 2023 to examine the case and reserved its decision until January 23, 2023. The listing of the Company's shares (ISIN: FR0010879056), which has been suspended sin...

 PRESS RELEASE

DEINOVE - Point sur la procédure de redressement judiciaire

DEINOVE - Point sur la procédure de redressement judiciaire DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et l'exploitation de la biodiversité bactérienne pour relever le défi urgent et planétaire de la résistance aux antimicrobiens, annonce que, dans le cadre de la procédure de redressement judiciaire ouverte le 7 novembre 2022, le Tribunal de Commerce de Montpellier s'est réuni le 13 janvier 2023 afin d'examiner l’affaire et a mis sa décision en délibéré au 23 janvier 2023. La cotation des actions de la Société (ISIN : FR0010879...

 PRESS RELEASE

DEINOVE - Update on the Receivership Proceedings

DEINOVE - Update on the Receivership Proceedings DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, announces that, in the context of the receivership proceedings (“procédure de redressement judiciaire”) opened on November 7, 2022, the Montpellier Commercial Court has met on December 16, 2022, and postponed the examination of the case to January 13, 2023. The continuation of the observation period (“période d'observation”) was requested by th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch